Alzheimer's Disease — IND-enabling studies underway
Two companion biologics that see Alzheimer's with precision and treat it at the source — unified by AI. Our published preclinical data show reversal of neurological damage.
Biologic A — Diagnostic
Makes damaged brain receptors visible on scan. Shows where memory circuitry is breaking down and how severely.
Biologic B — Treatment
Delivers a therapeutic protein directly to damaged receptors. Preclinical data show reversal of neurological damage.
AI Platform — SDPS
Tracks early warning signs, calculates personalized risk scores, and guides the treatment strategy in real time.
The approach
Alzheimer's has two devastating problems: we can't see it coming clearly enough, and we can't stop it once it starts. ExQor tackles both simultaneously with a unified system.
The MRI diagnostic biologic reveals exactly where damage is occurring. That scan then drives the treatment — telling us precisely where to target, how much to give, and whether it's working. No guesswork, no population-level dosing.
"Unlike lecanemab and donanemab, which only slow progression, our preclinical results show actual reversal of neurological damage — something no approved treatment has achieved."
Both biologics use a clathrin-mediated transport mechanism to cross the blood-brain barrier non-invasively — a platform discovery that underpins the entire system.
Intranasal administration. No surgery, no infusion center required — with home-based delivery potential.
MRI scans confirm treatment response over time. Objective evidence, not subjective reporting.
The SDPS platform scores individual risk and tailors dosing strategy — clinician decision support, fully documented.
Development status
ExQor is in IND-enabling studies targeting Phase 1 first-in-human trials. Our regulatory strategy leverages the diagnostic biologic as the entry point under FDA's companion diagnostic framework, with the treatment biologic following in sequence.
Market & patient impact
For the approximately 55 million people worldwide living with dementia — and the 131.5 million projected by 2050 — ExQor's unified approach represents a potential shift from disease management to disease reversal.
MRI diagnostic accessibility and home-based delivery potential could democratize access to advanced neurological care, reducing the global economic burden currently projected to reach $1.6 trillion by 2050. (Source: The Lancet)
We welcome inquiries from clinicians, researchers, and partners interested in our CNS diagnostic and therapeutic programs.
Email: info@exqor.com
Tel: +1 (617) 742-4422